The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Gerhardt Attard, M.D., Ph.D., from University College London, and colleagues conducted a double-blind trial that evaluated combining niraparib with AAP versus placebo and AAP in mCSPC with HRR gene ...

Among patients with prostate cancer with homologous recombination repair mutations (HRRm) receiving Akeega (niraparib and ...

A major international study led by UCL researchers has found that combining two cancer drugs could substantially slow the progression of a severe and often deadly form of prostate cancer in men with ...

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced ...

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

Multigene next-generation sequencing (NGS) performed directly on tumor tissue can accurately identify pathogenic variants in epithelial ovarian cancer (EOC), detecting both somatic and germline ...